Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology
Technical Perspectives on Biotech Stocks -- Vericel, Viking Therapeutics, VistaGen Therapeutics, and ZIOPHARM Oncology
NEW YORK, March 14, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on VCEL, VKTX, VTGN, and ZIOP which can be accessed for free by signing up to www.wallstequities.com/registration. Research reports have been issued by WallStEquities.com on Vericel Corp. (NASDAQ: VCEL), Viking Therapeutics Inc. (NASDAQ: VKTX), VistaGen Therapeutics Inc. (NASDAQ: VTGN), and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Biotechnology companies use live organisms or their products, such as bacteria or enzymes, to manufacture their medicines. Their drugs have a biological basis, while those of pharmaceutical companies have a chemical basis. All you have to do is sign up today for this free limited time offer by clicking the link below. www.wallstequities.com/registration
Vericel
Shares in Massachusetts headquartered Vericel Corp. rose 1.34%, ending Tuesday's trading session at $11.35. The stock recorded a trading volume of 940,359 shares. The Company's shares have surged 71.97% in the last month, 140.21% over the last three months, and 298.25% over the past year. The stock is trading 51.10% and 133.39% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have a Relative Strength Index (RSI) of 70.87.
On March 06(th), 2018, research firm Needham reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $5 a share to $15 a share.
On March 12(th), 2018, Vericel announced that it will host an Analyst and Investor Day on April 11(th), 2018, from 8:30 a.m. to 11:00 a.m. ET in New York City. The Company's executives will provide business updates and facilitate discussions with surgeon thought leaders, who currently use Vericel's products in their practices. Also speaking will be Dara Torres, world champion swimmer, best-selling author, five-time Olympian, and MACI(®) (autologous cultured chondrocytes on porcine collagen membrane) patient. Get the full research report on VCEL for free by clicking below at: www.wallstequities.com/registration/?symbol=VCEL
Viking Therapeutics
California headquartered Viking Therapeutics Inc.'s stock dropped 4.79%, closing the day at $5.76 with a total trading volume of 758,237 shares. The Company's shares have advanced 41.18% in the previous three months and 336.36% over the past year. The stock is trading 2.58% and 106.76% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Viking Therapeutics, which focuses on the development of therapies for metabolic and endocrine disorders, have an RSI of 45.36.
On March 06(th), 2018, Viking Therapeutics announced that its CEO, Brian Lian, Ph.D., will deliver a corporate presentation at H.C. Wainwright & Co.'s 2(nd) Annual NASH Investor Conference on March 19(th), 2018, at 10:40 p.m. ET at St. Regis Hotel in New York. Mr. Lian will also deliver a corporate presentation at Oppenheimer's 28(th) Annual Healthcare Conference on March 20(th), 2018, at 2:10 p.m. ET at Westin New York Grand Central Hotel in New York. Access the free research report on VKTX now by signing up at: www.wallstequities.com/registration/?symbol=VKTX
VistaGen Therapeutics
On Tuesday, shares in California headquartered VistaGen Therapeutics Inc. recorded a trading volume of 581,643 shares. The stock ended the day 4.42% higher at $1.30. The Company's shares have advanced 12.07% in the past month. The stock is trading above its 50-day moving average by 3.52%. Furthermore, shares of VistaGen Therapeutics, which engages in developing and commercializing product candidates for patients with central nervous system diseases, have an RSI of 52.37.
On March 05(th), 2018, VistaGen Therapeutics announced that Shawn Singh, CEO, will present at Oppenheimer's 28(th) Annual Healthcare Conference on March 21(st), 2018, at 8:00 a.m. ET in New York City. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VTGN at: www.wallstequities.com/registration/?symbol=VTGN
ZIOPHARM Oncology
Massachusetts headquartered ZIOPHARM Oncology Inc.'s stock climbed 1.14%, finishing yesterday's session at $4.44 with a total trading volume of 1.36 million shares. The Company's shares have advanced 14.14% in the last month and 0.23% in the previous three months. The stock is trading above its 50-day moving average by 7.45%. Additionally, shares of ZIOPHARM Oncology have an RSI of 59.33.
On March 01(st), 2018, ZIOPHARM Oncology announced its results for the quarter and year ended December 31(st), 2017. For Q4 2017, net loss applicable to the common stockholders was $18.3 million; R&D expenses were $11.2 million; and G&A expenses were $3.9 million. For the full year 2017, net loss applicable to the common stockholders was $73.3 million; R&D expenses were $45.1 million; and G&A expenses were $14.8 million. Aspiring Member, please take a moment to register below for your free research report on ZIOP at: www.wallstequities.com/registration/?symbol=ZIOP
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number:+21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Tom Johnson, anewmedias@gmail.com
View original content:http://www.prnewswire.com/news-releases/technical-perspectives-on-biotech-stocks----vericel-viking-therapeutics-vistagen-therapeutics-and-ziopharm-oncology-300613754.html
SOURCE Wall St. Equities
